It was the IPO that wasn't: A biotech firm hit the market and traded for six days, only to announce Friday that it wasn't issuing shares after all, thanks to a key investor's failure to follow through on a commitment to buy stock.

That meant all the investors who thought they had bought or sold shares in Vascular Biogenics Ltd. since it began trading hadn't.